DOCSLIB.ORG

Invirase, INN-Saquinavir

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Invirase, INN-Saquinavir ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT INVIRASE 200 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One capsule of Invirase contains saquinavir mesylate corresponding to 200 mg saquinavir. For excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Invirase is indicated for the treatment of HIV-1 infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products (see section 4.2). 4.2 Posology and method of administration Therapy with Invirase should be initiated by a physician experienced in the management of HIV infection. Adults and adolescents over the age of 16 years In combination with ritonavir The recommended dose of Invirase is 1000 mg (5 x 200 mg capsules) two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents. Invirase capsules should be swallowed whole and taken at the same time as ritonavir within 2 hours following a meal (see section 5.2). In combination with other protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors Dose reduction may be required when Invirase/ritonavir is administered with some other HIV protease inhibitors (e.g. nelfinavir, indinavir and delavirdine), since these drugs may increase saquinavir plasma levels (see section 4.5). Renal and hepatic impairment No dosage adjustment is necessary for patients with mild to moderate renal or mild hepatic impairment. Caution should be exercised in patients with severe renal or moderate hepatic impairment. Invirase/ritonavir is contraindicated in patients with severe hepatic impairment. (see sections 4.3 and 4.4) Paediatric and elderly patients There is only limited information on the safety and efficacy of saquinavir in HIV infected patients younger than 16 years and in adults over 60 years. Due to the significantly lower saquinavir plasma levels in children compared to adults, Invirase should not be used as the sole PI in children (see section 4.4). For further information on special patient groups, refer to section 4.4, and for pharmacokinetic interactions see sections 4.5. and 5.2. 2 4.3 Contraindications Invirase/ritonavir is contraindicated in patients with hypersensitivity to saquinavir, ritonavir or any of the excipients contained in the capsules. Invirase/ritonavir should not be given together with other drugs which may interact and result in potentially life threatening side effects. Drugs which should not be given with Invirase/ritonavir include terfenadine, astemizole, pimozide, cisapride, amiodarone, propafenone and flecainide (potential for life threatening cardiac arrhythmia), midazolam, triazolam (potential for prolonged or increased sedation, respiratory depression), simvastatin, lovastatin (increased risk of myopathy including rhabdomyolysis) and ergot alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and methylergonovine) (potential for acute ergot toxicity) (see section 4.5). Invirase/ritonavir is contraindicated in patients with severe hepatic impairment (see section 4.4). 4.4 Special warnings and special precautions for use Considerations when initiating Invirase therapy: Invirase should not be given as the sole protease inhibitor. Invirase should only be given in combination with ritonavir (see section 4.2). Patients should be informed that saquinavir is not a cure for HIV infection and that they may continue to acquire illnesses associated with advanced HIV infection, including opportunistic infections. Patients should also be advised that they might experience undesirable effects associated with co- administered medications. Liver disease: The safety and efficacy of saquinavir has not been established in patients with significant underlying liver disorders. Invirase/ritonavir is contraindicated in patients with severe hepatic impairment (see section 4.3). Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events. In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products. Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered. In cases of mild hepatic impairment no initial dosage adjustment is necessary at the recommended dose. The use of Invirase in combination with ritonavir in patients with moderate hepatic impairment has not been studied. In the absence of such studies, caution should be exercised, as increases in saquinavir levels and/or increases in liver enzymes may occur. There have been reports of exacerbation of chronic liver dysfunction, including portal hypertension, in patients with underlying hepatitis B or C, cirrhosis and other underlying liver abnormalities. Renal impairment: Renal clearance is only a minor elimination pathway, the principal route of metabolism and excretion for saquinavir being via the liver. Therefore, no initial dose adjustment is necessary for patients with renal impairment. However, patients with severe renal impairment have not been studied and caution should be exercised when prescribing saquinavir in this population. Patients with chronic diarrhoea or malabsorption: Only limited information on the safety and efficacy of saquinavir is available for patients suffering from chronic diarrhoea or malabsorption. It is unknown whether patients with such conditions could receive subtherapeutic drug levels. Young and elderly patients: The safety and efficacy of saquinavir in HIV-infected patients younger than 16 years have not been established. Limited information is available in children treated with Fortovase and none for children treated with Invirase as the sole protease inhibitor. Due to the 3 significantly lower saquinavir plasma levels in children compared with adults, neither Invirase nor Fortovase should be used as the sole protease inhibitor in children. When Fortovase (50 mg/kg bid) is co-administered with nelfinavir or ritonavir in children, saquinavir exposures are greatly increased and, when combined with ritonavir, may provide saquinavir exposures up to 2-fold greater than those achieved with Fortovase 1200 mg tid in adults. Only limited experience is available in patients older than 60 years. Lactose intolerance: Invirase 200 mg capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Use during pregnancy and lactation: See section 4.6. Patients with haemophilia: There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with protease inhibitors. In some patients additional factor VIII was given. In more than a half of the reported cases, treatment with protease inhibitors was continued or reintroduced if treatment had been discontinued. A causal relationship has been evoked, although the mechanism of action has not been elucidated. Haemophiliac patients should therefore be made aware of the possibility of increased bleeding. Diabetes mellitus and hyperglycaemia: New onset diabetes mellitus, hyperglycaemia or exacerbation of existing diabetes mellitus has been reported in patients receiving protease inhibitors. In some of these patients, the hyperglycaemia was severe and in some cases was also associated with ketoacidosis. Many patients had confounding medical conditions, some of which required therapy with agents that have been associated with the development of diabetes mellitus or hyperglycemia. Lipodystrophy: Combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV infected patients. The long-term consequences of these events are currently unknown. Knowledge about the mechanism is incomplete. A connection between visceral lipomatosis and PIs and lipoatrophy and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) has been hypothesised. A higher risk of lipodystrophy has been associated with individual factors such as older age, and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances. Clinical examination should include evaluation for physical signs of fat redistribution. Consideration should be given to the measurement of fasting serum lipids and blood glucose. Lipid disorders should be managed as clinically appropriate (see section 4.8.). Interaction with ritonavir: The recommended dose of Invirase and ritonavir is 1000 mg Invirase plus 100 mg ritonavir bid. Higher doses of ritonavir have been shown to be associated with an increased incidence of adverse events. Co-administration of saquinavir and ritonavir has led to severe adverse events, mainly diabetic ketoacidosis and liver disorders, especially in patients with pre-existing liver disease. Interaction with HMG-CoA reductase inhibitors: Caution must be exercised if Invirase/ritonavir is used concurrently with atorvastatin, which is metabolised to a lesser extent by CYP3A4. In this situation a reduced dose of atorvastatin should
Load more

Recommended publications
  • The Postmortem Distribution of Vardenafil (Levitra | in an Aviation
    Journal of Analytical Toxicology, Vol. 31, July/August 2007 The Postmortem Distribution of Vardenafil (Levitra| in an Aviation Accident Victim with an Unusually High Blood Concentration* Robert D. Johnson ~, Russell J. Lewis, and Mike K. Angler Downloaded from https://academic.oup.com/jat/article/31/6/328/682815 by guest on 27 September 2021 Civil Aerospace Medical Institute, Federal Aviation Administration, Analytical Toxicology and Accident Research Laboratory, AAM-610, CAMI Building, 6500 S. MacArthur Blvd., Oklahoma City, Oklahoma 73169-6901 I Abstract phodiesterase type 5 enzyme (PDE5) found predominantly in the penile corpus cavernosum (2-7). Vardenafil (tevitra) is one of the most widely prescribed Vardenafil undergoes hepatic metabolism, producing the treatments for erectile dysfunction. This report presents a active desethyl metabolite M1. M1 contributes to the ob- rapid and reliable method for the identification and quantification served pharmacological effects provided by vardenafil, as M1 of vardenafil in postmortem fluids and tissues, applies this method exhibits approximately 30% of the potency of the parent to a postmortem case, and describes the distribution of vardenafil in various fluids and tissues.This procedure utilizes sildenafil-d8, drug (1). Under steady-state conditions, the plasma concen- which is structurally closely related to vardenafil, as an tration of M1 is approximately 26% of that seen for vardenafil internal standard for more accurate and reliable quantitation. (1). After oral administration of vardenafil, peak plasma con- The method incorporates solid-phaseextraction and liquid centrations are obtained within 30-60 min (1). Vardenafil chromatography-tandem mass spectrometry (MS) and and its active metabolite have a terminal half-life of approx- MS-MS-MS utilizing an atmospheric pressure chemical imately 4-5 h (1).
    [Show full text]
  • Truvada (Emtricitabine / Tenofovir Disoproxil)
    Pre-exposure Prophylaxis (2.3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Recommended dose in HIV-1 uninfected adults: One tablet TRUVADA safely and effectively. See full prescribing information (containing 200 mg/300 mg of emtricitabine and tenofovir for TRUVADA. disoproxil fumarate) once daily taken orally with or without food. (2.3) TRUVADA® (emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use Recommended dose in renally impaired HIV-uninfected Initial U.S. Approval: 2004 individuals: Do not use TRUVADA in HIV-uninfected individuals if CrCl is below 60 mL/min. If a decrease in CrCl is observed in WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH uninfected individuals while using TRUVADA for PrEP, evaluate STEATOSIS, POST-TREATMENT ACUTE EXACERBATION OF potential causes and re-assess potential risks and benefits of HEPATITIS B, and RISK OF DRUG RESISTANCE WITH USE OF continued use. (2.4) TRUVADA FOR PrEP IN UNDIAGNOSED HIV-1 INFECTION -----------------------DOSAGE FORMS AND STRENGTHS-------------------­ See full prescribing information for complete boxed warning. Tablets: 200 mg/300 mg, 167 mg/250 mg, 133 mg/200 mg, and 100 Lactic acidosis and severe hepatomegaly with steatosis, mg/150 mg of emtricitabine and tenofovir disoproxil fumarate . (3) including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA. (5.1) --------------------------------CONTRAINDICATIONS-----------------------------­ TRUVADA is not approved for the treatment of chronic Do not use TRUVADA for pre-exposure prophylaxis in individuals with hepatitis B virus (HBV) infection. Severe acute unknown or positive HIV-1 status. TRUVADA should be used in exacerbations of hepatitis B have been reported in patients HIV-infected patients only in combination with other antiretroviral coinfected with HIV-1 and HBV who have discontinued agents.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,993,812 Tsoukas Et Al
    USOO5993812A United States Patent (19) 11 Patent Number: 5,993,812 TSOukas et al. (45) Date of Patent: Nov.30, 1999 54 METHOD OF DELAYING THE Brunkhorst et al., Infection 18:28-32, 1990. PROGRESSION OF AN INFECTION WITH Coyle et al., Changes in the Lymphocyte Count and Lym THE HUMAN IMMUNODEFICIENCY VIRUS phocyte Subsets After Splenectomy in Human Immunode ficiency Virus Infection, Letters and Correspondence, pp. 75 Inventors: Christos M. Tsoukas, Montreal; Barry 144-146. Michael Woloski, Winnipeg, both of DeSimone et al., Immunopharma. and Immunotoxic., Canada 13:447-458, 1991. Gringeri et al., British Journal of Haemotology, 80:337-340, 73 Assignee: Cangene Corporation, Winnipeg, 1992. Canada Gingör et al., Eur. J. Pediatr., 152:650–654, 1993. Mofenson and Moye, Pediatric Research, 33:80-S89, 1993. 21 Appl. No.: 08/835,400 Mofenson et al., Journal of Acquired Immune Deficiency 22 Filed: Apr. 7, 1997 Syndrome, 6:1103-1113, 1993. Schrappe-Bächer et al., Vox Sang, 59:3-14, 1990. Related U.S. Application Data Shearer et al., Ann. N.Y. Acad. Sci., pp. 35-51. Wagner et al., Arch. of Disease in Childhood., 63 Continuation-in-part of application No. 08/713,765, Sep. 13, 67:1267-1271, 1992. 1996, abandoned. Watson, et al., “Recombinant DNA”, Scientific American 60 Provisional application No. 60/003,756, Sep. 14, 1995. Books, Chapter 25. 51) Int. Cl. ............................ A61K 39/395; CO7K 1/00 Okesenhendeler, et al., “Anti-RH immunoglobulin therapy 52 U.S. Cl. ................... 424/130.1; 530/350, 530/388.7; for human immunodeficiency virus-related immune throm 424/142.1; 424/141.1; 424/153.1 bocytopenic purpura’, Blood, 71 (5) 1499-502.
    [Show full text]
  • Download Article PDF/Slides
    New Antiretrovirals in Development: Reprinted from The PRN Notebook,™ june 2002. Dr. James F. Braun, Editor-in-Chief. Tim Horn, Executive Editor. Published in New York City by the Physicians’ Research Network, Inc.,® John Graham Brown, Executive Director. For further information and other articles The View in 2002 available online, visit http://www.PRN.org All rights reserved. © june 2002. Roy “Trip” Gulick, md, mph Associate Professor of Medicine, Weill Medical College of Cornell University Director, Cornell Clinical Trials Unit, New York, New York Summary by Tim Horn Edited by Scott Hammer, md espite the fact that 16 antiretro- tiviral activity of emtricitabine was estab- Preliminary results from two random- virals are approved for use in the lished, with total daily doses of 200 mg or ized studies—FTC-302 and FTC-303—were United States, there is an indis- more producing the greatest median viral reported by Dr. Charles van der Horst and putable need for new anti-hiv com- load suppression: 1.72-1.92 log. Based on his colleagues at the 8th croi, held in Feb- pounds that have potent and these data, a once-daily dose of 200 mg ruary 2001 in Chicago (van der Horst, durable efficacy profiles, unique re- was selected for further long-term clinical 2001). FTC-302 was a blinded comparison sistance patterns, patient-friendly dosing study. “This is what we’re looking forward of emtricitabine and lamivudine, both in schedules, and minimal toxicities. To pro- to with emtricitabine,” commented Dr. combination with stavudine (Zerit) and vide prn with a glimpse of drugs current- Gulick.
    [Show full text]
  • VIDEX (Didanosine) Chewable/Dispersible Buffered Tablets
    Rx only VIDEXâ (didanosine) â VIDEX (didanosine) Chewable/Dispersible Buffered Tablets â VIDEX (didanosine) Buffered Powder for Oral Solution â VIDEX (didanosine) Pediatric Powder for Oral Solution (Patient Information Leaflet Included) WARNING FATAL AND NONFATAL PANCREATITIS HAVE OCCURRED DURING THERAPY WITH VIDEX USED ALONE OR IN COMBINATION REGIMENS IN BOTH TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS, REGARDLESS OF DEGREE OF IMMUNOSUPPRESSION. VIDEX SHOULD BE SUSPENDED IN PATIENTS WITH SUSPECTED PANCREATITIS AND DISCONTINUED IN PATIENTS WITH CONFIRMED PANCREATITIS (SEE WARNINGS). LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGUES ALONE OR IN COMBINATION, INCLUDING DIDANOSINE AND OTHER ANTIRETROVIRALS. FATAL LACTIC ACIDOSIS HAS BEEN REPORTED IN PREGNANT WOMEN WHO RECEIVED THE COMBINATION OF DIDANOSINE AND STAVUDINE WITH OTHER ANTIRETROVIRAL AGENTS. THE COMBINATION OF DIDANOSINE AND STAVUDINE SHOULD BE USED WITH CAUTION DURING PREGNANCY AND IS RECOMMENDED ONLY IF THE POTENTIAL BENEFIT CLEARLY OUTWEIGHS THE POTENTIAL RISK. (SEE WARNINGS AND PRECAUTIONS: PREGNANCY.) Page 4 of 39 DESCRIPTION â VIDEX (didanosine) is a brand name for didanosine (ddI), a synthetic purine nucleoside analogue active against the Human Immunodeficiency Virus (HIV). VIDEX Chewable/Dispersible Buffered Tablets are available for oral administration in strengths of 25, 50, 100, 150, and 200 mg of didanosine. Each tablet is buffered with calcium carbonate and magnesium hydroxide. VIDEX tablets also contain aspartame, sorbitol, microcrystalline cellulose, polyplasdone, mandarin-orange flavor, and magnesium stearate. VIDEX Buffered Powder for Oral Solution is supplied for oral administration in single- dose packets containing 100, 167, or 250 mg of didanosine. Packets of each product strength also contain a citrate-phosphate buffer (composed of dibasic sodium phosphate, sodium citrate, and citric acid) and sucrose.
    [Show full text]
  • Vardenafil Better Choice for Premature Ejaculation
    August 15, 2005 • www.familypracticenews.com Men’s Health 47 Vardenafil Better Choice for Premature Ejaculation BY ROBERT FINN (24%) of the men and was secondary (in On a self-rating scale of 0-8, where 0 Center but is now at the University of San Francisco Bureau most cases to erectile dysfunction) in the means PE almost never, 4 means PE about Hamburg. remaining 26 men (77%). half the time, and 8 means PE almost al- Self-ratings of sexual satisfaction, on a 0- S AN A NTONIO — Vardenafil improved After a 4-week run-in period, 17 men ways, the mean score was 6.14 at baseline, 5 scale, where 0 means not at all satisfied premature ejaculation more than sertra- were given 10-mg vardenafil 10 minutes 4.28 with sertraline, and 3.2 with varde- and 5 means extremely satisfied, averaged line, Frank Sommer, M.D., reported at the before intercourse for 6 weeks. The other nafil. 1.4 at baseline, 3.2 with sertraline, and 4.2 annual meeting of the American Urolog- 17 received 50 mg of sertraline 4 hours be- IVELT, as measured by a stopwatch, with vardenafil. In addition, the partners’ ical Association. fore intercourse. averaged 0.54 minutes at baseline, 2.87 sexual satisfaction showed significant in- Both vardenafil (Levitra), a phosphodi- After a 1-week washout period, the men minutes with sertraline, and 5.23 minutes creases for sertraline and even more so for esterase-5 inhibitor, and sertraline (Zoloft), who had been receiving sertraline with vardenafil, reported Dr. Sommer, vardenafil.
    [Show full text]
  • Fee-For-Service Preferred Drug List
    Prescription Drug Program Apple Health Medicaid: Fee-for-Service Preferred Drug List What is new in this version of the preferred drug list? Effective for dates of service on and after January 1, 2018, the Health Care Authority will make the following changes: Unless otherwise indicated in the drug class information, the authorization criteria is that the client must have tried and failed, or is intolerant to, at least two or more preferred drugs within the drug class unless contraindicated, not clinically appropriate, or only one drug is preferred. Drugs may have criteria that go beyond these basic criteria. Drug classes that are subject to the Therapeutic Interchange Program (TIP), are noted in the drug class information. For more information on TIP, see Theraputic Interchange Program in the Prescription Drug Program Medicaid Billing Guide. Drug Class Drug Name Change ACE Inhibitors Univasc Removed, no longer manufactured Galantamine Removed, no longer manufactured Alzheimer’s Drugs Aricept ODT Removed, no longer manufactured Exelon solution Removed, no longer manufactured Adrenaclick Non-Preferred, PA required Anaphylaxis Agents: Adrenalin Non-Preferred, PA required Epinephrine, Self Epinephrine Non-Preferred, PA required Injectable (new drug class) Epinephrine (Mylan only) Preferred Epipen 2-Pak/ JR 2-Pak Non-Preferred, PA required (Rev. 12/28/2017)(Eff. 1/1/2018) – 1 – Apple Health Medicaid PDL Prescription Drug Program Renamed drug class “Anticoagulants: Anticoagulants Entire class Factor XA and Thrombin Inhibitors.” Anticoagulants:
    [Show full text]
  • LEVITRA (Vardenafil Hcl) Tablets
    LEVITRA (vardenafil HCl) Tablets DESCRIPTION LEVITRA® is an oral therapy for the treatment of erectile dysfunction. This monohydrochloride salt of vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Vardenafil HCl is designated chemically as piperazine, 1-[[3-(1,4-dihydro-5- methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4- ethoxyphenyl]sulfonyl]-4-ethyl-, monohydrochloride and has the following structural formula: O O HN N x HCl x 3H2O N N O S O N N Vardenafil HCl is a nearly colorless, solid substance with a molecular weight of 579.1 g/mol and a solubility of 0.11 mg/mL in water. LEVITRA is formulated as orange, round, film-coated tablets with "BAYER" cross debossed on one side and "2.5", "5", "10", and "20" on the other side corresponding to 2.5 mg, 5 mg, 10 mg, and 20 mg of vardenafil, respectively. In addition to the active ingredient, vardenafil HCl, each tablet contains microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and red ferric oxide. CLINICAL PHARMACOLOGY Mechanism of Action Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection.
    [Show full text]
  • Non-Anntoated Product Monograph
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrTRIUMEQ dolutegravir, abacavir, and lamivudine tablets 50 mg dolutegravir (as dolutegravir sodium), 600 mg abacavir (as abacavir sulfate) and 300 mg lamivudine Antiretroviral Agent ViiV Healthcare ULC 245, boulevard Armand-Frappier Laval, Quebec H7V 4A7 Date of Revision: January 31, 2020 Submission Control No: 233245 © 2020 ViiV Healthcare group of companies or its licensor Trademarks are owned by or licensed to the ViiV Healthcare group of companies Page 1 of 61 TABLE OF CONTENTS PAGE PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................ 3 CONTRAINDICATIONS ........................................................................................... 4 WARNINGS AND PRECAUTIONS............................................................................ 4 ADVERSE REACTIONS.......................................................................................... 11 DRUG INTERACTIONS .......................................................................................... 19 DOSAGE AND ADMINISTRATION ........................................................................ 24 OVERDOSAGE....................................................................................................... 26 ACTION AND CLINICAL PHARMACOLOGY........................................................
    [Show full text]
  • Selected Properties of Maraviroc
    Selected Properties of Maraviroc Other names UK-427,857, MVC, Celsentri , Selzentry (US) Manufacturer ViiV Healthcare ULC Pharmacology/Mechanism of Maraviroc is a selective, slowly reversible, small molecule Action antagonist of the interaction between human CCR5 and HIV-1 gp120. Blocking this interaction prevents CCR5-tropic HIV-1 entry into cells . CCR5 antagonists target a discrete step in the viral entry pathway. The mechanism of HIV entry into the host CD4 T cells involves a sequence of molecular interactions between the virion envelope glycoprotein (Env) and host cell surface receptors. Normally, the gp120 Env subunit binds to CD4, and subsequent binding of HIV to the host cell’s coreceptors (CCR5 or CXCR4) causes a conformational change leading to membrane fusion into the host cell. Allosteric binding of a CCR5 antagonist results in a receptor conformation that the virus cannot bind to, thus interfering with the fusion process. NB: Use of maraviroc is not recommended in patients with dual/mixed or CXCR4-tropic HIV-1 as efficacy was not demonstrated in a phase 2 study of this patient group. The mean EC value (50% effective concentration) for Activity 50 maraviroc against HIV-1 group M isolates (clades A to J) and group O isolates ranged from 0.1 to 1.25 nM (0.05 to 0.64 ng/mL) in cell culture. Mean potency against a range of CCR5- tropic clinical primary isolates: IC 90 2.03 nM (1.04 ng/mL). In 973 treatment-experienced HIV-1-infected subjects in studies A4001027 and A4001028, the C , baseline viral load, baseline min CD4, cell count and overall sensitivity score (OSS) were found to be important predictors of virologic success (defined as viral load < 400 copies/mL at 24 weeks).
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]